However, YC-1 has been found to possess additional properties; it is also a nitric oxide synthetase (NOS)-independent activator of soluble guanylyl cyclase (sGC), which has been used clinically to treat thrombosis and hypertension (16), and it blocks NF-κB activity in tumor cells (17). Here, NFKB1 is linked to neoplasm.